# Governor's COVID-19 Vaccine Advisory Group

Thursday, January 14, 2021







#### **Before We Begin**

- Please remain muted
- Raise Hand
- Feel free to use Comments section



#### Agenda

1.	Welcome and Roll Call	Commissioner Gifford
		Dr. Eadie
3.	Vaccine Program Update  a. Metrics b. Phase 1b roll-out c. Access expansion  Subcommittee Reports a. Key Decisions and Recommendations b. Next Steps c. Questions and Discussion with the Group	Benjamin Bechtolsheim  Nichelle Mullins  Sen. Somers  Jason Schwartz
4.	Open Discussion	Advisory Group members
5.	New Directions to Subcommittees	Advisory Group members
6.	Next Advisory Group Meeting  a. Upcoming Subcommittee Meetings	Advisory Group members Subcommittee Co-Chairs
7.	Wrap-Up	Mike Mozzer  Benjamin Bechtolsheim
8.	Adjourn	



## Welcome

Commissioner Deidre Gifford, MD Reginald Eadie, MD



**CURRENT ESTIMATES** 

#### State of CT Dec. & Jan. supply planning






2<sup>nd</sup> dose



2<sup>nd</sup> dose



Take numbers with grain of salt – projections are changing frequently as new information becomes available



#### **Key metrics:**

#### Doses shipped and administered

FIRST DOSE REPORT

Facility Name	Total 1st Doses Administered	Weeks 1-4 1st Dose Allocation	% of Weeks 1-4 1st Dose
racincy radine	Through 1/13	(Dec 14 - Jan 10)	Allocation Administered
OVERALL TOTAL ALLOCATION USED	154,994	211,325	73%
LTCF SUB-TOTAL	35,239	77,025	46%
NON-LTCF SUB-TOTAL	119,755	134,300	89%

SECOND DOSE REPORT

Facility Name	Total 2nd Doses Administered Through 1/13	Weeks 1-4 2nd Dose Allocation (Dec 14 - Jan 10)	% of Weeks 1-4 2nd Dose Allocation Administered
OVERALL TOTAL ALLOCATION USED	16,041	31,200	51%
LTCF SUB-TOTAL	2,419	15,600	16%
NON-LTCF SUB-TOTAL	13,622	15,600	87%

OVERALL DOSE REPORT

Facility Name	Overall Doses Administered Through 1/13	Weeks 1-4 Overall Allocation (Dec 14 - Jan 10)	% of Weeks 1-4 Overall Allocation Administered
OVERALL TOTAL ALLOCATION USED	171,035	242,525	71%
LTCF SUB-TOTAL	37,658	92,625	41%
NON-LTCF SUB-TOTAL	133,377	149,900	89%



#### **Overview of Phase 1b**

Age 75+	277,000
Age 64 - 75	353,000
People 16-64 with one high risk condition	362,000
Frontline essential workers *	325,000
Congregate settings	50,000
Total	1,367,000

Assuming 75% uptake and 50k doses per week, Phase 1b to take 20 weeks

Through May

Greater supply could accelerate roll-out



#### A range of access efforts are underway

- Working with medical groups who can administer vaccine to conduct outreach to 75+ patients
- Enrolling an expanded set of providers to enable easier access to individuals 75+, including: Additional provider practices and pharmacies
- Vaccine access line can support scheduling for individuals with limited technology access
- Launching program to ensure <u>on-site</u> coverage at a range of congregate settings, building on testing programs and current LTCF approach
- Continuing to map vaccine access with Social Vulnerability Index



- If you have already heard from your provider no further action needed
- If you use email and can book an appointment online enroll at ct.gov/COVIDVaccine
- If you need support access phone line will be available
- Several providers also offering direct scheduling



### **Allocation Subcommittee**

Nichelle Mullins and Zita Lazzarini

Phase 1b Recommendations – January 5, 2021 Allocation Subcommittee Meeting

- The subcommittee endorsed the ACIP recommendations for Phase 1b:
  - Persons aged 75 and over
  - Frontline Essential Workers



The subcommittee recommended expanding ACIP's list of Frontline Essential Workers as follows:

- Agricultural workers to include farmworkers
- Food service workers (moved from Phase 1c to Phase 1b)
- Charitable food service workers (food banks/kitchens), including those who deliver meals to the elderly
- Solid waste workers as well as wastewater and water workers (moved from Phase 1c to Phase 1b)
- Clarify that health department inspectors (restaurants, etc.) are included in 1b



The subcommittee also recommended including Congregate Setting staff and residents in Phase 1b.



January 12, 2021 Allocation Subcommittee meeting

The subcommittee recommended that the following individuals be included in Phase 1b:

- Individuals aged 65-74
- Individuals aged 16-64 with at least one CDC designated comorbidity



The subcommittee also recommended that the Department of Public Health:

- Phase the 1b roll-out based on risk of mortality and severe illness
- Explicitly address issues of equity and the disparate impacts of COVID in both the phase-in of these groups as well as the implementation of the vaccine roll-out



#### **Plan Moving Forward**

- Work with Department of Public Health to review the Frontline Essential Workers list
- Determine Phase 1c recommendations
- Work with DPH on implementation recommendations and oversight



# **Communications Subcommittee**

Sen. Heather Somers and Dr. Joseph Quaranta



- Subcommittee Recommendations Issued to Full Advisory Co-chairs
  - Use multiple communication channels to reach diverse audiences
  - Utilize the Science Subcommittee as a subject matter expert panel to provide testimonials about the importance and safety of the vaccine
  - Engage the Communications Subcommittee to deliver/amplify state messages
- Actions
  - Subcommittee meeting 12/23
  - Co-chair coordination with Commissioner Gifford, State Comms and Vax team
  - DPH updates/announcements shared w/ and by committee
  - Forums (e.g. Sen. Somers, 1199)



#### **Plan Moving Forward**

- Coordinating forums held by subcommittee members
  - Dates
  - Audience info
  - Technology Needs
  - Linking with a Scientific Subcommittee SME
- Phase 1B
  - Residents who are 75 and older (Outreach to focus on availability, eligibility, where to get vax)
  - Residents and staff of congregate settings
  - Frontline essential workers
  - Residents between the ages of 65 and 74
  - Residents between the ages of 16 and 64 who have underlying health conditions that put them at greater risk of the virus
- Provider outreach
- Vaccine Hesitancy
- Continue coordination with Comms and Vaccination team



## Science Subcommittee

Jason Schwartz and David Banach, MD

#### **Key Updates**

- Subcommittee meeting, 12/28
  - Topic: Vaccine safety surveillance and reporting systems
  - Guest: Kathy Kudish, DPH
- Contributions to communication and educational efforts
  - Visit to Communications Subcommittee meeting, 12/23
  - Participated in virtual public 'town hall', 1/5
  - Presentation and Q&A with Greater New London Clergy Association,
     1/14
  - Participating in Q&A sessions with 1199 union, 1/15

#### **Plan Moving Forward**

- Further contributions to communication and educational efforts
- Throughout winter/spring: consideration of additional vaccine candidates currently in Phase 3 clinical trials
  - Johnson & Johnson (Janssen)
  - AstraZeneca
  - Novavax
- Next subcommittee meeting, 1/25



# DPH Open Discussion





# Thank you for your participation